ARCA biopharma, Inc.

NasdaqCM:ABIO 株式レポート

時価総額：US$48.0m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ARCA biopharma マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Tom Keuer

最高経営責任者

US$400.8k

報酬総額

CEO給与比率84.8%
CEO在任期間9.5yrs
CEOの所有権0.005%
経営陣の平均在職期間データなし
取締役会の平均在任期間7.3yrs

経営陣の近況

Recent updates

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Apr 04
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Sep 24
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 03

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Mar 18
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Nov 27
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

CEO報酬分析

ARCA biopharma の収益と比較して、Tom Keuer の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$401kUS$340k

-US$5m

Sep 30 2023n/an/a

-US$5m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$449kUS$340k

-US$10m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$421kUS$339k

-US$19m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$631kUS$285k

-US$10m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$304kUS$283k

-US$5m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$327kUS$303k

-US$8m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$457kUS$302k

-US$18m

報酬と市場: Tomの 総報酬 ($USD 400.80K ) は、 US市場 ($USD 667.63K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Tomの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Tom Keuer (65 yo)

9.5yrs

在職期間

US$400,802

報酬

Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...

取締役

名称ポジション在職期間報酬所有権
Linda Grais
Independent Director17.1yrsUS$162.50k0%
$ 0
Anders Hove
Independent Director7.3yrsUS$150.00k0%
$ 0
Robert Conway
Independent Chairman of the Board10.8yrsUS$195.00k0.34%
$ 165.5k
Jacob Ma-Weaver
Director2yrsUS$130.00kデータなし
James Flynn
Independent Director1.5yrsUS$40.00k0%
$ 0

7.3yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: ABIOの 取締役会 は 経験豊富 であると考えられます ( 7.3年の平均在任期間)。